Partners' Directory

  Home   Search   Join the Partnership   Login

Contact General Specializations in Countries Contribution to the Global Plan Declaration

View this partner's profile

Organization Contact Information

Name: Pharmacogenomics Research Center (PGRC)
Street 1: # 633-165, Gaegum-Dong, Jin-gu Busan,
Street 2:
City: Busan
Post Code: 614-735
Country: Republic of Korea
Phone: +82-51-890-6709
Organization Email:
Web Site:,
Other Online Presence:

Focal Point Contact Information

Salutation: Prof.
First Name: Jae-Gook
Last Name: Shin MD, PhD.
Title: Director, Pharmacogenomics Research Center (PGRC)
Phone: +82-51-890-6709, +82-10-8520-7971

Alternate Focal Point Contact Information

Salutation: Mr.
First Name: Md. Masud
Last Name: Parvez
Title: Coordinator, TB personalized medicine project
Phone: +82-51-890-6416, +82-10-3149-5897

General Information

Board Constituency: Private sector
Is your organization legally registered in your country: Yes
If yes, please enter your registration number:
Organization Type - Primary: Academic / Research Institution
Organization Type - Secondary: None
Organization Description:
Pharmacogenomics Research Center (PGRC), one of the leading Pharmacogenomics research center. We do in vitro, in vivo phamracogenomics (PGx) research and clinical trial for personalized medicine. We conduct therapeutic drug monitoring (TDM) in our center. Now we have taken a mission towards personalized medicine for Tuberculosis (TB) treatment. During TB treatment many adverse events and resistance occurs, one of the major cause is multi-drug regimen for TB. Therefore more drug-drug interactions (DDIs) possibility and till to date there were limited information regarding anti-TB drugs based on Metabolic enzymes and membrane transporters.
In this research project we have included commonly prescribed and FDA approved anti-TB drugs for metabolism, transporter and pharmacogenomics study. We gave efforts to explore unknown genetic association with the drugs such as metabolism, transporter and molecular mechanism associated with the host and pathogen. We have found several novel characteristics of the drugs that can affect on PK/PD/AE during conventional use. Some drugs showed DDI possibilities within TB drugs. Now we have initiated program for conducting PBPK modeling,simulation and therapeutic drugbmonitoring (TDM) of our data towards real time clinical trial to get optimum therapy for TB. In personalized medicine for TB approach, patients could be stratified before they start treatment, in order to avoid ineffective treatments and prevent adverse drug reactions, resulting in more efficient therapy and the reduction of resistance.
Do you know about the UNHLM declaration:

Specializations / Areas of Work

Delivery of health services and care
Provision of drugs, diagnostics and commodities
Research and Development
Technical Assistance

Other Organization Information

Total number of staff in your organization: 51 - 99
Number of full-time staff who are directly involved with TB: 26 - 50
Number of part-time staff who are directly involved with TB: 11 - 25
Number of volunteers who are directly involved with TB: 26 - 50
How did you hear about the Stop TB Partnership: Attendance at a TB related event
If you were informed or referred by another partner of the Stop TB Partnership please tell us who:
Why do you wish join the Stop TB Partnership: Information on developments within the TB world
Are you a member of a Stop TB national partnership: No
Are you in contact with your national TB programme: Yes
Please tell us how your organization is contributing to your country's national TB control plan:
We have a plenty of well qualified national and international researchers, collaborator by which we could explore the new era of personalized medicine in TB. PGRC is contributing to elucidate the hidden pharmacogenetic and Pharmacogenomics association with TB in Korean population. We have Korean population PGx data to input our research towards clinically to improve TB treatment.

Geographical Reach

Which country is your headquarters located in: Republic of Korea
Which countries do you do operate in:
(This includes countries you are conducting activities in)
Republic of Korea


Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below:

Drug-Resistant TB:
The importance of the area within the MDR-TB is collaborating with the discussion, research and public policy development assistance to tuberculosis, which can contribute to the reduction of social inequalities, especially in health. The area identified in the community, possible cases of tuberculosis, forwards them to the Health Services and promotes access and adherence to treatment, increasing the number of patients cured. Training of health-care professionals in drug-resistant patients; organization and monitoring drug distribution to MDR patients. exploring the MDR-TB facts and molecular mechanism to target therapy and personalized medicine approach to improve MDR-TB management.

Training of professionals in conducting tuberculin treatment with HIV by concomitant administration of the drugs based on pharmacogenomics data; Training of physicians to attend coinfected patients (TB/HIV) with drug resistant TB; Expansion of DOT procedures. Elucidation of DDIs between TB-HIV drugs.

New TB Drugs:
PGRC has the Global Excellence Clinical Trial Center in Busan Paik Hospital, where many clinical trial has been conducted. We have taken strategy to give new and existing TB drugs TDM and Clinical trial to improve Personalized medicine for TB strategy.

Fundamental Research:
PGRC is involve with fundamental research for TB such as MDR/XDR/RR-TB. Macrophage associated with TB. Molecular mechanism of TB and Management to stop TB.


Declaration of interests:
No conflicts of interest were delacred.

Application date: December 29, 2014
Last updated: May 14, 2018